TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06709495: Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcoma

Sponsor: David S Shulman, MD · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 63 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06709495 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06709495 Rescue Dossier →